U.S. markets closed

Dr. Reddy's Laboratories Limited (RDY)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
54.04-0.02 (-0.04%)
At close: 04:00PM EDT
54.04 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Previous Close54.06
Bid52.77 x 900
Ask54.20 x 800
Day's Range53.49 - 54.13
52 Week Range47.88 - 66.16
Avg. Volume221,170
Market Cap8.984B
Beta (5Y Monthly)0.25
PE Ratio (TTM)23.81
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJul 08, 2021
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
19% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for RDY

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Dr. Reddy's Laboratories Ltd
    Analyst Report: Dr. Reddy's Laboratories LimitedHeadquartered in India, Dr. Reddy’s Laboratories develops and manufactures generic pharmaceutical products sold across the world. The company specializes in low-cost, easy-to-produce small-molecule generic drugs and active pharmaceutical ingredients. Its drug portfolio in recent years has included biosimilar drug launches in select emerging markets and has shifted toward injectables and more complex generic products. Geographically, the company’s sales are well dispersed across North America, India, and other emerging markets.
    Fair Value
    Economic Moat
    2 months agoMorningstar
View more
  • Benzinga

    Intercept Settles Ocaliva Litigation With Reddy's Lab

    Intercept Pharmaceuticals Inc (NASDAQ: ICPT) and its subsidiary Intercept Pharma Europe Limited settled patent litigation with Dr. Reddy’s Laboratories Ltd (NYSE: RDY). The litigation concerns the submission by Dr. Reddy’s of an Abbreviated New Drug Application seeking approval to market a generic version of Ocaliva (obeticholic acid) 5 mg and 10 mg tablets before the expiration of the Company’s U.S. patents. Related: Intercept Shares Jump After Reissuing Annual Guidance. Under the terms of the

  • Zacks

    Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

    Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

  • Zacks

    Dr. Reddy's (RDY) Q1 Earnings Increase Y/Y, Sales Increase

    Dr. Reddy's (RDY) earnings and sales increase year over year in first-quarter fiscal 2023.